Futu Holdings UP Fintech Tumble as China Securities Regulator Cracks Down on CrossBorder Trading Alibaba and Other USListed Chinese Stocks Decline Market Expert Advises Caution Amid Geopolitical Risks June Quarter Earnings to Guide Market Sentiment San Francisco Giants GM Points Finger at Rookie Manager Amid Franchise Concerns UK Hottest Day of Year Boosts Travel Sectors Amid Bank Holiday Queues Smallcase Managers Remain Bullish on Nifty 50 See Potential for 2800030000 by FY27End Oppenheimer Suggests Golub Capitals Fair Value May Align Closely with Book Value Everest Group Q1 2026 Earnings Strong EPS Beat Highlights Underwriting Strength 36Kr Holdings KRKR Q1 2023 Earnings Net Loss Deepens as Revenue Visibility Remains Limited RPT Q1 2026 Earnings Net Loss Exceeds Expectations as Real Estate Headwinds Persist Legacy Education Inc LGCY Q1 2026 Earnings Strong EPS Beat Despite Revenue Headwinds and Stock Pullback LULU Q1 2026 Earnings EPS Beats Estimates Stock Rises Kochav Defense Acquisition Corp KCHV Holds Steady at 1032 Stability in a Volatile SPAC Market Marten Transport Bounces 25 Off Support Approaching Key Resistance Consensus Cloud Solutions CCSI Gains 26 as Support Holds Near 2888 Zone Voya Global Equity Dividend and Premium Opportunity Fund IGD Edges Higher as Price Approaches Key Resistance Ames National Corporation ATLO Holds Steady as Key Levels Define Trading Range CDW Corporation Stock Wall Street Sentiment and Market Outlook DUK Q1 2026 Earnings Utility Giant Beats Estimates as Regulatory Gains Offset Cost Pressures VSE Corporation VSEC Shows Strength Stock Advances 21 Amid Positive Momentum USPH Q1 2026 Earnings EPS Misses Estimates by 1725 Stock Rises 33 Kyntra Bio Inc KYNB Q1 2026 Earnings WiderthanExpected Loss Disappoints PFGC Q1 2026 Earnings EPS Beats Estimates Despite Negative Market Reaction iQSTEL Inc Q4 2025 Earnings EPS Misses Estimates Significantly Stock Declines PRCT Q1 2026 Earnings EPS Narrowly Beats Estimates as Stock Slips PSKY Q1 2026 Earnings EPS Surges Past Estimates with 5182 Beat Kalaris Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Biotech